Cardio Diagnostics Holdings Inc CDIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDIO is a good fit for your portfolio.
News
-
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually
-
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
-
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
-
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session
-
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
-
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
-
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
-
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.69–0.70
- 52-Week Range
- $0.18–3.56
- Bid/Ask
- $0.67 / $0.70
- Market Cap
- $15.02 Mil
- Volume/Avg
- 50,648 / 481,492
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 509.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 9
Valuation
|
Metric
|
CDIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.76 |
Price/Sales | 509.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDIO
|
|---|---|
Quick Ratio | 1.53 |
Current Ratio | 3.29 |
Interest Coverage | −0.24 |
Quick Ratio
CDIO
Profitability
|
Metric
|
CDIO
|
|---|---|
Return on Assets (Normalized) | −198.49% |
Return on Equity (Normalized) | −399.83% |
Return on Invested Capital (Normalized) | −150.12% |
Return on Assets
CDIO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ngrqhyqcb | Xhq | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rmjgjglqz | Qqttwb | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cvbpvdtk | Dwpyhd | $98.1 Bil | |
MRNA
| Moderna Inc | Kbpmtrhq | Sdns | $42.2 Bil | |
ARGX
| argenx SE ADR | Ltjwrbrpb | Skc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vfwtdymhc | Cbqj | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dfqgxtjcz | Qqfgnbb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wnyrfxdr | Kjgwj | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rbxpthnkh | Vwfcbw | $12.5 Bil | |
INCY
| Incyte Corp | Dmbqtrp | Xzvgn | $11.7 Bil |